

**Table S2.** Univariate and multivariable analyses of distant metastasis-free survival

	Univariate			Multivariable		
	HR	95% CI	p-value	HR	95% CI	p-value
Age (yr)	0.98	0.95–1.02	0.263			
Sex (male vs. female)	1.55	0.75–3.21	0.234			
ECOG performance status (1 vs. 0)	1.58	0.75–3.35	0.229			
Disease extent (BRPC vs. LAPC)	1.00	0.30–3.28	0.994			
Tumor location (head vs. other)	0.94	0.47–1.86	0.852			
Induction CT duration (mo)	0.93	0.71–1.23	0.632			
Induction CT (FFX vs. GnP)	0.97	0.29–3.21	0.961			
Grade (I/II vs. III)	0.90	0.43–1.90	0.790			
CTV (cm <sup>3</sup> )	1.00	0.99–1.01	0.147			
Baseline CA19-9 (U/mL)	1.00	0.99–1.00	0.627			
Pre-SBRT CA19-9 (U/mL)	1.01	1.00–1.01	<0.001			
Baseline total bilirubin (mg/dL)	0.95	0.81–1.04	0.336			
Pre-SBRT						
ALC ( $\times 10^3/\mu\text{L}$ )	0.86	0.48–1.44	0.592			
NLR	0.97	0.83–1.05	0.567			
Post-SBRT						
ALC ( $\times 10^3/\mu\text{L}$ )	0.92	0.32–2.41	0.869			
NLR	1.06	0.93–1.16	0.365			

ECOG, Eastern Cooperative Oncology Group; BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer; CT, chemotherapy; FFX, FOLFIRINOX; GnP, gemcitabine/nab-paclitaxel; CTV, Clinical target volume; CA19-9, cancer antigen 19-9; SBRT, stereotactic body radiation therapy; ALC, absolute lymphocyte count; ANC, absolute neutrophil count; NLR, neutrophil to lymphocyte ratio; HR, hazard ratio; CI, confidence interval.